Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.86 |
| ▸ | DRD3 | P35462 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10357591 | 0.98 | OPRK1 (0.96) | OPRK1DRD2DRD3MAPTNFKB1 | |
| SCHEMBL30697493 | 0.92 | DRD2 (1.00) | OPRK1DRD2DRD3MAPTNFKB1 | |
| SCHEMBL30839518 | 0.92 | DRD2 (1.00) | OPRK1DRD2DRD3MAPTNFKB1 | |
| SCHEMBL265949 | 0.92 | DRD2 (1.00) | OPRK1DRD2DRD3MAPTNFKB1 | |
| SCHEMBL9135070 | 0.92 | DRD2 (1.00) | OPRK1DRD2DRD3MAPTNFKB1 | |
| SCHEMBL5722322 | 0.92 | DRD2 (1.00) | OPRK1DRD2DRD3MAPTNFKB1 | |
| Hydrochloric Acid SCHEMBL9317222 | 0.91 | DRD2 (0.96) | OPRK1DRD2DRD3MAPTNFKB1 | |
| Bromide SCHEMBL354391 | 0.91 | DRD2 (0.96) | OPRK1DRD2DRD3MAPTNFKB1 | |
| Bromide SCHEMBL5722309 | 0.91 | DRD2 (0.96) | OPRK1DRD2DRD3MAPTNFKB1 | |
| Water SCHEMBL9305270 | 0.91 | DRD2 (0.96) | OPRK1DRD2DRD3MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-6117910-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0799189-A4 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0799189-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018602-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| US-4308266-A | 1,2,3,4-Tetrahydro-2-piperazinyl-naphthalenes for treating hypertension | SANDOZ LTD. (CH) | 1981-12-29 | — | — | US | disclosed |
| EP-0000395-B1 | 2-PIPERAZINOTETRALINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES | SANDOZ AG (CH) | 1981-01-07 | — | — | EP | disclosed |
| EP-0000395-A1 | 2-Piperazinotetraline derivatives, their preparation and their use as medicines | SANDOZ AG (CH) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | OPRK1 176/4885DRD2 1634/4885DRD3 1688/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | OPRK1 176/4885DRD2 1634/4885DRD3 1688/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | OPRK1 176/4885DRD2 1634/4885DRD3 1688/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | OPRK1 158/4885DRD2 3348/4885DRD3 2618/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | OPRK1 176/4885DRD2 1634/4885DRD3 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.